A Pharmacokinetic Subtrial in Adolescent Patients With Hereditary Angioedema Type I or II Participating in the KVD900-302 Trial
Latest Information Update: 10 Jan 2025
At a glance
- Drugs Sebetralstat (Primary)
- Indications Hereditary angioedema
- Focus Pharmacokinetics; Registrational
- Sponsors KalVista Pharmaceuticals
Most Recent Events
- 16 Jul 2024 Planned End Date changed from 30 Jan 2026 to 30 Jun 2026.
- 16 Jul 2024 Planned primary completion date changed from 30 Jan 2026 to 30 Jun 2026.
- 23 Sep 2022 Planned initiation date changed from 22 Aug 2022 to 1 Sep 2022.